Zacks: Brokerages Expect Eli Lilly and Company (LLY) to Announce $1.08 Earnings Per Share

Analysts expect that Eli Lilly and Company (NYSE:LLY) will report $1.08 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Eli Lilly and’s earnings, with the lowest EPS estimate coming in at $1.05 and the highest estimate coming in at $1.11. Eli Lilly and reported earnings of $0.95 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 13.7%. The firm is expected to announce its next quarterly earnings results on Tuesday, January 30th.

According to Zacks, analysts expect that Eli Lilly and will report full year earnings of $4.21 per share for the current fiscal year, with EPS estimates ranging from $4.13 to $4.25. For the next financial year, analysts forecast that the business will report earnings of $4.64 per share, with EPS estimates ranging from $4.50 to $4.84. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Eli Lilly and.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the prior year, the firm posted $0.88 earnings per share. The company’s quarterly revenue was up 9.0% compared to the same quarter last year.

A number of research firms recently issued reports on LLY. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Leerink Swann increased their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $89.76.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 770,000 shares of company stock worth $64,669,850 in the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of LLY. BlackRock Inc. raised its position in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the period. Janus Henderson Group PLC raised its position in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after acquiring an additional 9,223,251 shares during the period. Dodge & Cox raised its position in Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after acquiring an additional 5,964,955 shares during the period. Renaissance Technologies LLC raised its position in Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after acquiring an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. raised its position in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares during the period. Institutional investors own 75.68% of the company’s stock.

Eli Lilly and (NYSE LLY) opened at $83.99 on Friday. Eli Lilly and has a one year low of $64.18 and a one year high of $89.09. The stock has a market cap of $92,503.00, a PE ratio of 20.54, a P/E/G ratio of 1.85 and a beta of 0.34. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.48%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Eli Lilly and Company (LLY) to Announce $1.08 Earnings Per Share” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://transcriptdaily.com/2017/11/10/zacks-brokerages-expect-eli-lilly-and-company-lly-to-announce-1-08-earnings-per-share.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply